High-cited favorable studies for COVID-19 treatments ineffective in large trials
View ORCID ProfileJohn P.A. Ioannidis
doi: https://doi.org/10.1101/2022.01.11.22269097
John P.A. Ioannidis
Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA

Data Availability
All data produced in the present work are contained in the manuscript
Posted January 14, 2022.
High-cited favorable studies for COVID-19 treatments ineffective in large trials
John P.A. Ioannidis
medRxiv 2022.01.11.22269097; doi: https://doi.org/10.1101/2022.01.11.22269097
Subject Area
Subject Areas
- Addiction Medicine (164)
- Allergy and Immunology (417)
- Anesthesia (93)
- Cardiovascular Medicine (867)
- Dermatology (98)
- Emergency Medicine (251)
- Epidemiology (8597)
- Gastroenterology (391)
- Genetic and Genomic Medicine (1775)
- Geriatric Medicine (170)
- Health Economics (376)
- Health Informatics (1252)
- Health Policy (625)
- Hematology (198)
- HIV/AIDS (380)
- Medical Education (193)
- Medical Ethics (51)
- Nephrology (214)
- Neurology (1692)
- Nursing (97)
- Nutrition (252)
- Oncology (934)
- Ophthalmology (265)
- Orthopedics (104)
- Otolaryngology (172)
- Pain Medicine (115)
- Palliative Medicine (40)
- Pathology (256)
- Pediatrics (541)
- Primary Care Research (210)
- Public and Global Health (3877)
- Radiology and Imaging (629)
- Respiratory Medicine (525)
- Rheumatology (208)
- Sports Medicine (159)
- Surgery (191)
- Toxicology (36)
- Transplantation (101)
- Urology (76)